Inhibrx Biosciences/$INBX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Inhibrx Biosciences
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Ticker
$INBX
Sector
Primary listing
Employees
110
Headquarters
Website
INBX Metrics
BasicAdvanced
$1.4bn
-
-$8.39
-
-
Price and volume
Market cap
$1.4bn
52-week high
$155.29
52-week low
$13.92
Average daily volume
459k
Financial strength
Current ratio
6.463
Quick ratio
6.105
Long term debt to equity
-848.538
Total debt to equity
-859.986
Interest coverage (TTM)
-9.45%
Profitability
EBITDA (TTM)
-120.706
Gross margin (TTM)
-7,697.54%
Net profit margin (TTM)
-10,014.23%
Operating margin (TTM)
-9,465.46%
Effective tax rate (TTM)
-0.00%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-36.06%
Return on equity (TTM)
-354.69%
Valuation
Price to revenue (TTM)
1,116.456
Price to book
-64.96
Price to tangible book (TTM)
-64.96
Price to free cash flow (TTM)
-11.001
Free cash flow yield (TTM)
-9.09%
Free cash flow per share (TTM)
-8.503
Growth
Revenue change (TTM)
550.00%
Earnings per share change (TTM)
-107.52%
3-year revenue growth (CAGR)
47.76%
3-year earnings per share growth (CAGR)
27.79%
What the Analysts think about INBX
Analyst ratings (Buy, Hold, Sell) for Inhibrx Biosciences stock.
INBX Financial Performance
Revenues and expenses
INBX Earnings Performance
Company profitability
INBX News
AllArticlesVideos
Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study
Benzinga·1 month ago
Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study
MarketBeat·1 month ago
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
Benzinga·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs